Monalizumab, a humanized anti-NKG2A antibody(formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignanciesA Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies and other cancers.IPH2201 studiesFirst Clinical Data For Monalizumab As A Single Agent In Cancer Patients Show Favorable Safety Profile
Mechanism of action Monalizumab is a monoclonal antibody targeted at NKG2A.AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips It is a checkpoint inhibitor.
References